Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December.
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:
| Evercore ISI 3rd Annual HealthCONx Conference | ||
| Date: | Thursday, December 3rd, 2020 | |
| Time: | 1:00 - 1:45 pm ET in Track 1 | |
| Panel: | Easy Pills to Swallow: Oral Drugs for Large Endo Markets | |
| Presenter: | Dr. Scott Struthers, Founder & CEO | |
| Piper Sandler’s 32nd Annual Healthcare Conference | ||
| Date: | Tuesday - Thursday, December 1st - 3rd, 2020 | |
| Time: | On demand | |
| Presenter: | Dr. Scott Struthers, Founder & CEO, and Dr. Alan Krasner, Chief Medical Officer | |
| Webcast: | Pre-recorded fireside chats are available for the annual Piper Sandler Healthcare Conference on the Events section on the Company’s website as well as on the Piper Sandler conference website. | |
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 program in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit https://crinetics.com.
Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464
Investors / Media:
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
(212) 915-2577
Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957
